Data as of Dec 19
| +0.075 / +0.48%|
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. These technology platforms are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, CA.
|Howard W. Robin||President, Chief Executive Officer & Director|
|John Nicholson||Chief Financial Officer & Senior Vice President|
|Stephen K. Doberstein||Chief Scientific Officer & Senior Vice President|
|Ivan P. Gergel||Chief Medical Officer & SVP-Drug Development|
|Gilbert M. Labrucherie||Secretary, Senior Vice President & General Counsel|